Pope Leo XIV denounced how investments in artificial intelligence and high-tech weaponry were leading the world into a "spiral of annihilation," as he called for peace in the Middle East and Ukraine. (Image credit: Gregorio Borgia)
Pope Leo XIV denounced how investments in artificial intelligence and high-tech weaponry were leading the world into a "spiral of annihilation," as he called for peace in the Middle East and Ukraine. (Image credit: Gregorio Borgia)
XtockImages Japan’s producer prices rose 4.9% year-over-year in April 2026, up from 2.9% in March and exceeding expected growth of 3%. This was the fastest increase since May 2023, driven by high-energy costs from supply chain issues due to the war in Iran. On a monthly basis, producer prices increased 2.3%, picking up from a 1.0% gain in March and marking the strongest monthly rise since April 20...
XtockImages Japan’s producer prices rose 4.9% year-over-year in April 2026, up from 2.9% in March and exceeding expected growth of 3%. This was the fastest increase since May 2023, driven by high-energy costs from supply chain issues due to the war in Iran. On a monthly basis, producer prices increased 2.3%, picking up from a 1.0% gain in March and marking the strongest monthly rise since April 2014. The Nikkei 225 Index fell 1.6% to below 61,700, while the broader Topix Index slipped 0.5% to 3,860 on Friday, extending declines from the previous session. The Japanese yen weakened to around 158.5 per dollar and was set to post a weekly loss of more than 1%. More on Japan economy EWJ: The Land Of The Rising Sun Is Set For Continued Growth JPY Intervention - Unilateral Or Joint Will Be Key The Yen Recovers On Verbal Intervention Asian tech rally drives mild gains as U.S.-China summit pressures Beijing shares Japan’s top banks to get Anthropic’s Mythos AI model in coming weeks - report
China’s stock investors boosted their leveraged bets to an all-time high, helping fuel a record-setting run on technology stocks amid easing geopolitical tensions and earnings resilience. The outstanding value of margin trading on the mainland’s exchanges reached 2.86 trillion yuan (US$420.8 billion) on Thursday, rising to a record for a seventh straight day, according to the data by China Securit...
China’s stock investors boosted their leveraged bets to an all-time high, helping fuel a record-setting run on technology stocks amid easing geopolitical tensions and earnings resilience. The outstanding value of margin trading on the mainland’s exchanges reached 2.86 trillion yuan (US$420.8 billion) on Thursday, rising to a record for a seventh straight day, according to the data by China Securities Finance. Leveraged traders poured the borrowed funds mainly into electronics, semiconductor and...
Chinese President Xi Jinping hosted the visiting US leader Donald Trump at Zhongnanhai in the heart of Beijing on Friday, the final day of Trump’s trip. Trees and roses The ancient trees and roses at Zhongnanhai drew Trump’s eye and sparked some light-hearted banter between the two leaders. As they strolled through the Chinese leaders’ compound, Xi pointed out ancient trees, some of them a few hun...
Chinese President Xi Jinping hosted the visiting US leader Donald Trump at Zhongnanhai in the heart of Beijing on Friday, the final day of Trump’s trip. Trees and roses The ancient trees and roses at Zhongnanhai drew Trump’s eye and sparked some light-hearted banter between the two leaders. As they strolled through the Chinese leaders’ compound, Xi pointed out ancient trees, some of them a few hundred years old. “They live that long?” Trump asked, a smiling Xi noting that some of the trees were...
SpyGlass Pharma, Inc. press release ( SGP ): Q1 GAAP EPS of -$0.69. Cash, cash equivalents and short-term investments of $251.0 million on March 31, 2026, are expected to fund planned operations through 2028. Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. More on SpyGlass Phar...
SpyGlass Pharma, Inc. press release ( SGP ): Q1 GAAP EPS of -$0.69. Cash, cash equivalents and short-term investments of $251.0 million on March 31, 2026, are expected to fund planned operations through 2028. Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. More on SpyGlass Pharma, Inc. SpyGlass Pharma, Inc. GAAP EPS of -$5.72 Historical earnings data for SpyGlass Pharma, Inc. Financial information for SpyGlass Pharma, Inc.
winhorse/iStock Unreleased via Getty Images I'm keeping ORIX Corporation ( IX ) (8591.T) as a " Buy"-rated name. ORIX's earnings growth accelerated meaningfully in FY26 (YE Mar), which also surpassed management's expectations. Looking ahead, the firm is guiding for an impressive high-teens increase in net income for the new fiscal year. The stock's valuations are attractive with a re-rating potent...
winhorse/iStock Unreleased via Getty Images I'm keeping ORIX Corporation ( IX ) (8591.T) as a " Buy"-rated name. ORIX's earnings growth accelerated meaningfully in FY26 (YE Mar), which also surpassed management's expectations. Looking ahead, the firm is guiding for an impressive high-teens increase in net income for the new fiscal year. The stock's valuations are attractive with a re-rating potential of +54%. Its current price-to-book multiple isn't reflective of the improving financial return profile. The company's better-than-anticipated shareholder returns and financial numbers for 9MFY26 (YE Mar) were detailed in my prior Feb 10, 2026, write-up . FY26 Net Profit Was A Positive Surprise The group released a set of slides unveiling its annual financials on May 11. ORIX's YoY bottom-line expansion improved substantially from FY2025's +1.6% to FY2026's +27.2%. Its recent full-year earnings of ¥447 billion were also +2% ahead of the management guidance. I've identified the "Environment and Energy (E&E)," "Private Equity and Concession (PE&C)", and Insurance divisions as outperformers. E&E reversed from a -¥5 billion operating loss in the previous fiscal year to record a +¥116 billion EBIT for FY26. ORIX's presentation deck highlighted its "ROE-centered portfolio optimization" which led to "gains on sale of Greenko, Ormat, Zeeklite shares." The company-wide ROE widened by 160 bps to 10.4% during the same period. The PE segment's portfolio firms witnessed profit growth across the board. Its airport operating franchise in Kansai also benefited from higher throughput. These drove a 27% rise in PE&C's FY2026 operating income to ¥126 billion. Last fiscal year, the enterprise's insurance-related operations registered an EBIT of ¥64 billion, representing a 38% increase. The "introduction of higher-value products" and a shift towards "corporate and wealthier clients" were cited as profitability enhancement levers in the results slides. My take is that investors had a favorabl...
(RTTNews) - China Gold International Resources Corp. Ltd. (CGG.TO) announced a profit for its first quarter that Increased, from the same period last year
(RTTNews) - China Gold International Resources Corp. Ltd. (CGG.TO) announced a profit for its first quarter that Increased, from the same period last year